

PATENT

Appl. No.
Amdt. dated August 19, 2003]
Preliminary Amendment

3, 5-13, 32-35

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. cancelled

2. cancelled

3. (original) A nucleic acid construct comprising a SIV-1 gag gene having
the coding sequence of the gag gene set forth in Figure 3. → 6AC

4. cancelled

5. (currently amended) A vector comprising the nucleic acid construct of
Claim 1, 2, 3 or 4.

6. (currently amended) A transformed host cell comprising the nucleic acid
construct of Claim 1, 2, 3 or 4.

7. (original) A transformed host cell of Claim 6 wherein said cell is a
eukaryote.

8. (original) The host cell of Claim 7 wherein said cell is a human cell.

9. (original) A transformed host cell of Claim 6 wherein said cell is a
prokaryote.

10. (original) The host cell of Claim 9 wherein said cell is E. coli.

I. GAC N.A.

536/23,72

II. MRTI USING II

424/198.1, 209.1
Page 3 of 5

III. RNU N.A.

536/23,72

PATENT

Appl. No.
Amdt. dated August 19, 2003]
Preliminary Amendment

11. (currently amended) A pharmaceutical composition comprising the
nucleic acid construct of Claim 1, 2, 3 or 4 and a pharmaceutically acceptable carrier.

12. (original) A method for inducing antibodies in a mammal comprising
administering to a mammal a composition of claim 11, wherein said nucleic acid construct is
present in an amount which is effective to induce said antibodies in said mammal.

13. (original) A method for inducing cytotoxic T lymphocytes in a mammal
comprising administering to a mammal a composition of claim 11, wherein said nucleic acid construct is present in an amount which is effective to induce cytotoxic T lymphocytes in said
mammal.

Claims 14-31 cancelled

32. (original) A nucleic acid construct comprising a SIV-1 env gene having
the coding sequence of the env gene set forth in Figure 16. — SIV-1 env CTE

33. (original) A vector comprising the nucleic acid construct of claim 32.

34. (original) A transformed host cell comprising the nucleic acid construct of
claim 32.

35. (original) A pharmaceutical composition comprising the nucleic acid
construct of claim 32 and a pharmaceutically acceptable carrier.